Free Access
Med Sci (Paris)
Volume 33, Number 1, Janvier 2017
Matériaux pour la médecine de demain
Page(s) 81 - 84
Section Nouvelles
Published online 25 January 2017
  1. Dorothée G, Aucouturier P. Les réponses immunitaires adaptatives contre le peptide amyloïde Aβ dans la maladie d’Alzheimer : leçons et perspectives. Med Sci (Paris) 2011 ; 27 : 938–940. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  2. Ozmen L, Collin L. Prévenir la progression de la pathologie Tau par immunothérapie passive. Med Sci (Paris) 2015 ; 31 : 132–134. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  3. Wisniewski T, Goni F. Immunotherapeutic approaches for Alzheimer’s disease. Neuron 2015 ; 85 : 1162–1176. [CrossRef] [PubMed] [Google Scholar]
  4. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999 ; 400 : 173–177. [CrossRef] [PubMed] [Google Scholar]
  5. Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012 ; 69 : 198–207. [CrossRef] [PubMed] [Google Scholar]
  6. Reardon S. Antibody drugs for Alzheimer’s show glimmers of promise. Nature 2015 ; 523 : 509–510. [CrossRef] [PubMed] [Google Scholar]
  7. Sperling RA, Jack CR, Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s association research roundtable workgroup. Alzheimers Dement 2011 ; 7 : 367–385. [CrossRef] [PubMed] [Google Scholar]
  8. Lathuiliere A, Mach N, Schneider BL. Encapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system. Int J Mol Sci 2015 ; 16 : 10578–10600. [CrossRef] [PubMed] [Google Scholar]
  9. Lathuiliere A, Cosson S, Lutolf MP, et al. A high-capacity cell macroencapsulation system supporting the long-term survival of genetically engineered allogeneic cells. Biomaterials 2014 ; 35 : 779–791. [CrossRef] [PubMed] [Google Scholar]
  10. Lathuiliere A, Bohrmann B, Kopetzki E, et al. Genetic engineering of cell lines using lentiviral vectors to achieve antibody secretion following encapsulated implantation. Biomaterials 2014 ; 35 : 792–802. [CrossRef] [PubMed] [Google Scholar]
  11. Lathuiliere A, Laversenne V, Astolfo A, et al. A subcutaneous cellular implant for passive immunization against amyloid-beta reduces brain amyloid and tau pathologies. Brain 2016 ; 139 : 1587–1604. [CrossRef] [PubMed] [Google Scholar]
  12. Xiang X, Werner G, Bohrmann B, et al. TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance. EMBO Mol Med 2016 ; 8 : 992–1004. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.